Tag : ReAffirms


FDA Reaffirms Safety of Pimavanserin in PD Psychosis

The agency’s postmarket review finds no new or unexpected safety risks associated with the antipsychotic, but some prescribing patterns are ‘potentially concerning.’ News Alerts Source...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy